• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Psychemedics Corporation Welcomes Drew Reynolds to Its Board of Directors and Announces the Retirement of Harry Connick From His Director Role

    3/22/22 8:30:00 AM ET
    $PMD
    Medical Specialities
    Health Care
    Get the next $PMD alert in real time by email

    ACTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, is pleased to welcome Andrew "Drew" M. Reynolds to the Psychemedics Board of Directors effective April 4th, 2022. Mr. Reynolds will also serve as a member of the Audit, Compensation, and Nominating and Governance Committees.

    Mr. Reynolds currently serves as a board director and independent consultant to a number of companies. He has over 25 years-experience and has held positions in strategy, corporate development, sales and marketing, both domestically and internationally. He has a strong track record of driving profitable growth and creating value at private and public technology companies. During his career, he has been an advocate for shareholders and the effective use of investor capital in both his operating and board roles.

    "We are extremely pleased that Drew has agreed to join our Board of Directors," said Raymond C. Kubacki, CEO. "Drew comes to us with extensive global experience and a wide range of skills in revenue-driving positions such as business development, sales/marketing, mergers and acquisitions and partnerships. In addition, Drew's direct, hands-on operational experience, as well as his work in the trucking market, one of our key verticals, makes him an exceptionally strong match for us. He will be a terrific addition as we plan to accelerate Psychemedics' growth and profitability during these challenging but exciting times ahead."

    The Company is also announcing that Harry Connick plans to retire from the Psychemedics Board of Directors effective April 4th, 2022. Mr. Connick has served as a board director for over 18 years and has been a member of the Audit, Compensation, and Nominating and Governance Committees. Previously, Mr. Connick served with great distinction as the District Attorney of the Orleans Parish in Louisiana for 30 years.

    "I would like to thank Harry for his long-term contributions to our company's Board; and for his commitment and dedication to addressing the serious problem of drug abuse. Harry is, and always has been, a difference-maker in helping other people. His leadership role and focus on deterring high school students from making poor choices about drugs has been extremely significant for the young people of our country, as well as for our Company."

    BIOGRAPHY OF DREW REYNOLDS

    Currently, Drew serves as an independent director for AddSecure, a Stockholm, Sweden based provider of Internet of Things (IoT) solutions including security, surveillance, and safety communication systems; Idle Smart, an early-stage provider of idle and battery power management solutions for large transport vehicles; and Linxup (fka Agilis Systems), a SaaS-based provider of trucking fleet telematics and tracking solutions. Drew is also on the advisory board of Locomation, an autonomous trucking company providing aftermarket solutions for large commercial transport vehicles. Beyond his board responsibilities, Drew provides consulting services to a variety of enterprise software and IoT companies, and these engagements are typically focused on business strategy or supporting buy-side and sell-side M&A.

    Over the course of his career as a corporate development executive, Drew has created clear strategies by working collaboratively with boards and with executive team colleagues. By using his relationship skills to work cross-functionally, and by managing and coaching teams, he has executed on critical initiatives that support those strategies. This work has contributed to the creation of billions of dollars in equity value. Prior to his role as an advisor, Drew spent almost six years as the SVP of Global Business and Corporate Development at Fleetmatics, PLC, a provider of truck fleet tracking and mobile workforce management software. At Fleetmatics, Drew reported to the CEO and was responsible for strategy, M&A, integration, and partnerships. After supporting Fleetmatics' IPO process, he executed six cross-border acquisitions that expanded the company's product set, created its mainland European business, and made a substantial impact on its subscriber growth. Drew also built and managed the company's data sales effort, as well as leading its expansion into Latin America. Fleetmatics was acquired by Verizon for $2.4B in November of 2016, and he managed that transaction for the Company.

    Before Fleetmatics, Drew spent over a decade in leadership roles in strategy and corporate development at three publicly traded companies, Art Technology Group, an ecommerce software provider that was sold to Oracle in 2011 for $1B, Hyperion Solutions, financial and analytics software applications that was sold to Oracle for $3.3B, and CMGI, a venture capital and investment company. During that period, he managed acquisitions and subsequent integrations of public, private, and international companies.

    Earlier in his career, he was a management consultant advising large enterprises across a range of industries on strategic and operational issues. He also spent four years as a software sales executive at Transition Systems, Inc., a healthcare focused software solutions company. Drew was the largest revenue contributor and recognized as ‘Salesman of the Year' during the year of its successful IPO. Drew received his MBA from Cornell University and his undergraduate degree from Dartmouth College.

    ABOUT PSYCHEMEDICS

    Psychemedics Corporation is the world's largest provider of hair testing for the detection of drugs of abuse. The Company's patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods. The Psychemedics web site is www.psychemedics.com.

    Contact: Raymond C. Kubacki, Chairman, President and CEO

    Phone: (978) 206-8220



    Primary Logo

    Get the next $PMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/17/24 8:29:49 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/12/24 8:41:51 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Director Kamin Peter bought $3,312,823 worth of shares (1,409,712 units at $2.35) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/5/24 6:05:08 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Powell Anderson Capital Partners Llc bought $305,439 worth of shares (159,700 units at $1.91) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/17/24 8:29:49 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Large owner Powell Anderson Capital Partners Llc bought $231,849 worth of shares (86,991 units at $2.67) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/12/24 8:41:51 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Director Kamin Peter sold $753,664 worth of shares (320,708 units at $2.35) (SEC Form 4)

      4 - PSYCHEMEDICS CORP (0000806517) (Issuer)

      12/12/24 5:15:34 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    SEC Filings

    See more
    • SEC Form 15-12G filed by Psychemedics Corporation

      15-12G - PSYCHEMEDICS CORP (0000806517) (Filer)

      1/2/25 4:10:54 PM ET
      $PMD
      Medical Specialities
      Health Care
    • SEC Form 25 filed by Psychemedics Corporation

      25 - PSYCHEMEDICS CORP (0000806517) (Filer)

      12/13/24 8:00:57 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13E3/A filed by Psychemedics Corporation

      SC 13E3/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/10/24 4:46:00 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Psychemedics Releases 2025 Workforce Insights Report

      DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industry, analyzing hundreds of thousands of samples collected in 2024 across a wide range of sectors, including transportation, manufacturing, healthcare, government, and more. The report reveals critical workforce trends and emerging threats empl

      6/16/25 9:00:00 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights

      DALLAS, March 03, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair drug testing, is proud to announce the launch of its innovative Quartile Reporting feature. This industry-first enhancement empowers organizations with unprecedented insights into drug test results, enabling data-driven decision-making and fostering safer, more productive workplaces. The new Quartile Reporting feature allows clients to see where a candidate's or employee's test results fall within a range of positive reports collected over the past 12 months. By segmenting results into four quartiles – Lower, Median, Upper, and Highest – this advanced reporting provides real-time context and bench

      3/3/25 9:00:00 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Announces Reverse and Forward Stock Split

      DALLAS, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD) (the "Company"), the world's leading provider of hair testing for drugs of abuse, today announced that, following the approval of the Company's stockholders at its Annual Meeting of Stockholders held on November 25, 2024, the Company's Board of Directors has approved a 1-for-5,000 reverse stock split of its common stock (the "Reverse Stock Split") followed immediately by a 5,000-for-1 forward stock split of its common stock (the "Forward Stock Split," and together with the Reverse Stock Split, the "Stock Split"), to be effective at 5:01 p.m. and 5:02 p.m., Eastern Time, respectively, on Tuesday, December 3, 202

      12/2/24 8:10:00 AM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

      SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/12/24 5:15:40 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Psychemedics Corporation

      SC 13G/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/6/24 9:18:20 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Psychemedics Corporation

      SC 13D/A - PSYCHEMEDICS CORP (0000806517) (Subject)

      12/5/24 6:04:48 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

      ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in steering the financial trajectory of the organization. Bringing over a decade of extensive experience to her new position, Ms. Mehalik possesses a robust background in acco

      11/27/23 9:00:00 AM ET
      $NBSE
      $PMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • Psychemedics Corporation Reports Third Quarter 2023 Financial Results

      ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company's revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.02) per diluted share, for the comparable period last year. The Company has initiated a series of restructuring changes that will align costs with current revenue trends. Res

      11/9/23 5:00:59 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Appoints Shannon Shoemaker as Chief Revenue Officer

      ACTON, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world's largest provider of hair testing for drugs of abuse, is pleased to announce the appointment of Shannon Shoemaker as its new Chief Revenue Officer. In this role, Shoemaker will be responsible for overseeing the company's revenue generation and growth strategies. With an exceptional track record of leadership and a strong background in revenue growth and optimization, Shoemaker brings a wealth of experience to her new position. Her appointment marks a significant milestone for Psychemedics Corporation as it continues to expand its presence in the rapidly evolving field of substance abuse testing. "We are

      9/21/23 5:00:00 PM ET
      $PMD
      Medical Specialities
      Health Care

    $PMD
    Financials

    Live finance-specific insights

    See more
    • Unveiling the Future of Drug Testing: Psychemedics Introduces Advanced 5-Panel Drug Screen

      ACTON, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- In an era marked by relentless change and the pressing need to adapt, Psychemedics, a pioneer in the drug screening industry, proudly announces the launch of a revolutionary, Advanced 5-Panel Drug Screen. This groundbreaking offering will transform the way organizations safeguard their workplaces, shifting the spotlight from marijuana to the paramount threat of fentanyl. Complemented by the detection of cocaine, opioids, PCP, and amphetamines, the advanced panel is a leap forward in drug screening technology. As we grapple with an ongoing labor shortage and with marijuana's legal landscape evolving in 49 states, it's clear that the time for

      10/27/23 11:00:00 AM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Reports Second Quarter 2023 Financial Results

      ACTON, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2023. The Company's revenue for the quarter ended June 30, 2023, was $5.5 million versus $6.5 million for the quarter ended June 30, 2022, a decrease of 15%. Net loss for the quarter ended June 30, 2023, was $(726,000) or $(0.13) per diluted share, versus net loss of $(338,000) or $(0.06) per diluted share, for the comparable period last year. In the second quarter, the labor shortage continued to have an adverse impact on our clients' use of hair testing in hirin

      8/11/23 5:10:31 PM ET
      $PMD
      Medical Specialities
      Health Care
    • Psychemedics Corporation Reports First Quarter 2023 Financial Results and Declares Cash Dividend

      ACTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world's largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2023, and the declaration of a cash dividend of $0.07 per share to be paid on June 8, 2023, to shareholders of record as of May 25, 2023. The Company's revenue for the quarter ended March 31, 2023, was $5.9 million versus $6.5 million for the quarter ended March 31, 2022, a decrease of 10%. Net loss for the quarter ended March 31, 2023, was $(384,000) or $(0.07) per diluted share, versus net income of $39,000 or $0.01 per diluted share, for the comparable period last ye

      5/9/23 5:30:00 PM ET
      $PMD
      Medical Specialities
      Health Care